Source comparison
Comparison: AOD-9604 vs Other Lipolytic Peptides
AOD-9604 Beta-3 adrenergic receptor agonist 30–40 minutes None. Operates independently of insulin signalling 3× higher receptor density in visceral vs subcutaneous adipose tissue Critical. One amino acid substitution eliminates receptor binding Fragment 176-19
This comparison does not assign a generated winner or score.
- AOD-9604
- Beta-3 adrenergic receptor agonist
- 30–40 minutes
- None. Operates independently of insulin signalling
- 3× higher receptor density in visceral vs subcutaneous adipose tissue
- Critical. One amino acid substitution eliminates receptor binding
- Fragment 176-191 (hGH)
- Identical to AOD-9604 (same peptide, different naming convention)
- None
- Identical to AOD-9604
- Critical. Synthesis purity determines efficacy
- CJC-1295
- GHRH analog. Stimulates endogenous GH release
- 6–8 days
- Moderate. Triggers GH-mediated insulin resistance at high doses
- Non-selective. Affects all adipose depots equally
- Moderate. Longer half-life tolerates minor impurities better
- Tesamorelin
- GHRH analog (FDA-approved for HIV lipodystrophy)
- 26–38 minutes
- Moderate. Can elevate fasting glucose in pre-diabetic subjects
- Preferentially reduces visceral adipose tissue in clinical trials
- High. Pharmaceutical-grade synthesis required for human use
- Tesofensine
- Triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine)
- 8 days
- Low. Minimal impact on insulin or glucose metabolism
- Non-selective. Systemic thermogenic effect rather than localised lipolysis
- High. Extremely potent; dosing precision critical